FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to organ transplantation and clinical laboratory diagnostics. The level of expression of microRNA-339 is determined in the diagnosis of graft myocardial fibrosis in cardiac recipients in peripheral blood plasma, and at a level above -5.24 relative units, the presence of graft myocardial fibrosis is diagnosed.
EFFECT: method allows reducing the time of diagnosis and its reliability at any time after transplantation, as well as to increase the survival rate of recipients and improve the results of heart transplantation.
1 cl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR NON-INVASIVE DIAGNOSIS OF MYOCARDIAL FIBROSIS IN CARDIAC TRANSPLANT RECIPIENTS | 2021 |
|
RU2760093C1 |
| METHOD FOR NON-INVASIVE DIAGNOSIS OF MYOCARDIAL FIBROSIS IN DONOR HEART RECIPIENTS | 2021 |
|
RU2761470C1 |
| METHOD FOR DIAGNOSING ACUTE TRANSPLANT REJECTION IN TRANSPLANTED HEART RECIPIENTS | 2020 |
|
RU2758994C1 |
| METHOD FOR DIAGNOSING ACUTE REJECTION OF TRANSPLANT IN TRANSPLANTED HEART RECIPIENT | 2020 |
|
RU2758973C1 |
| METHOD FOR PREOPERATIVE PREDICTION OF ACUTE CELLULAR REJECTION OF A TRANSPLANTED HEART | 2022 |
|
RU2798948C1 |
| METHOD FOR DIAGNOSING BRONCHIAL OBSTRUCTION IN LUNG TRANSPLANT RECIPIENTS | 2020 |
|
RU2750973C1 |
| METHOD FOR DIAGNOSING BRONCHIAL OBSTRUCTION IN LUNG TRANSPLANT RECIPIENT | 2020 |
|
RU2760195C1 |
| METHOD FOR DIAGNOSING BACTEREMIA ASSOCIATED WITH GRAM-NEGATIVE MICROORGANISMS IN HEART OR LUNG RECIPIENTS | 2021 |
|
RU2780280C1 |
| METHOD FOR NONINVASIVE DIAGNOSIS OF MYOCARDIAL FIBROSIS OF CARDIAC ALLOGRAFT | 2021 |
|
RU2772054C1 |
| METHOD FOR NON-INVASIVE DIAGNOSIS OF MYOCARDIAL FIBROSIS OF TRANSPLANTED HEART AT A LONG POST-TRANSPLANTATION PERIOD IN RECIPIENTS SUFFERING ACUTE REJECTION | 2019 |
|
RU2709193C1 |
